Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
Bianco A, Lucchini M, Totaro R, Fantozzi R, De Luca G, Di Lemme S, Presicce G, Evangelista L, Di Tommaso V, Pastorino R, De Fino C, De Arcangelis V, Centonze D, Mirabella M. Bianco A, et al. Among authors: di tommaso v. Neurotherapeutics. 2021 Oct;18(4):2598-2607. doi: 10.1007/s13311-021-01106-6. Epub 2021 Sep 7. Neurotherapeutics. 2021. PMID: 34494237 Free PMC article.
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis.
Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M; MS Study Group of the Italian Neurological Society. Amato MP, et al. Among authors: di tommaso v. Neurology. 2010 Nov 16;75(20):1794-802. doi: 10.1212/WNL.0b013e3181fd62bb. Neurology. 2010. PMID: 21079181
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.
Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'Maison F, Oreja-Guevara C, Boz C, Lugaresi A, Girard M, Grammond P, Iuliano G, Fiol M, Cabrera-Gomez JA, Fernandez-Bolanos R, Giuliani G, Lechner-Scott J, Cristiano E, Herbert J, Petkovska-Boskova T, Bergamaschi R, van Pesch V, Moore F, Vella N, Slee M, Santiago V, Barnett M, Havrdova E, Young C, Sirbu CA, Tanner M, Rutherford M, Butzkueven H; MSBasis Study Group. Meyniel C, et al. PLoS One. 2012;7(6):e38661. doi: 10.1371/journal.pone.0038661. Epub 2012 Jun 29. PLoS One. 2012. PMID: 22768046 Free PMC article.
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
Pastò L, Portaccio E, Ghezzi A, Hakiki B, Giannini M, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi GL, Solaro C, Totaro R, Tola MR, Di Tommaso V, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Pastò L, et al. Among authors: di tommaso v. BMC Neurol. 2012 Dec 31;12:165. doi: 10.1186/1471-2377-12-165. BMC Neurol. 2012. PMID: 23276328 Free PMC article.
Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Edite Rio M, van Pesch V, Amato MP, Iuliano G, Slee M, Verheul F, Cristiano E, Fernández-Bolaños R, Poehlau D, Saladino ML, Deri N, Cabrera-Gomez J, Vella N, Herbert J, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, McDonnell G, Hawkins S, Kee F, Butzkueven H; MSBase study group. Hughes SE, et al. Mult Scler. 2014 May;20(6):739-46. doi: 10.1177/1352458513507816. Epub 2013 Oct 9. Mult Scler. 2014. PMID: 24107309
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group. Totaro R, et al. Among authors: di tommaso v, di carmine c, di ioia m. Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):147-54. doi: 10.1177/039463201402700201. Int J Immunopathol Pharmacol. 2014. PMID: 25004826 Free article.
"Nail loss after teriflunomide treatment: A new potential adverse event".
Mancinelli L, Amerio P, di Ioia M, Di Tommaso V, De Luca G, Onofrj M, Lugaresi A. Mancinelli L, et al. Among authors: di tommaso v, di ioia m. Mult Scler Relat Disord. 2017 Nov;18:170-172. doi: 10.1016/j.msard.2017.09.029. Epub 2017 Sep 25. Mult Scler Relat Disord. 2017. PMID: 29141803
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
35 results